C1q/肿瘤坏死因子相关蛋白6(CTRP6)抑制卵巢癌细胞的增殖和迁移

C1q tumor necrosis factor-related protein 6(CTRP6) inhibits the proliferation and migration of ovarian cancer cells

目的探讨C1q/肿瘤坏死因子相关蛋白6(CTRP6)对卵巢癌细胞增殖和转移的抑制作用。方法 ELISA分别检测卵巢癌患者与健康志愿者血清,SKOV3、3AO和HO8910上皮性卵巢癌细胞与IOSE80正常卵巢上皮细胞培养上清中CTRP6的水平;采用人CTRP6重组蛋白处理高转移性卵巢癌HO8910细胞,ELISA检测HO8910细胞白细胞介素8(IL-8)和血管内皮生长因子(VEGF)的分泌水平,采用CCK-8法检测细胞增殖、TranswellTM侵袭实验检测细胞侵袭能力;采用CTRP6小干扰RNA(CTRP6 siRNA)或CTRP6抗体处理HO8910细胞,采用CCK-8法检测细胞的增殖能力、细胞划痕实验检测细胞迁移能力。结果CTRP6在卵巢癌患者血清和上皮性卵巢癌细胞培养上清中水平降低;CTRP6重组蛋白处理HO8910细胞48 h后,细胞增殖和侵袭能力显著下降;利用siRNA抑制CTRP6表达后,细胞增殖和迁移能力显著增强;CTRP6抗体处理后,细胞增殖和迁移能力亦显著增强。结论 CTRP6在卵巢癌患者血清和上皮性卵巢癌细胞上清中水平降低;CTRP6可阻断IL-8/VEGF通路从而抑制上皮性卵巢癌细胞的增殖和迁移。

Objective To explore the role of C1 q tumor necrosis factor-related protein 6（ CTRP6） in the proliferation and migration of ovarian cancer cells. Methods ELISA was used to detect the serum CTRP6 contents in ovarian cancer patients and healthy volunteers,and CTRP6 levels in the supernatants of SKOV3,3AO and HO8910 epithelial ovarian cancer cell lines and IOSE80 normal ovarian epithelial cells. Recombinant human CTRP6 protein was applied to treat HO8910 cells. After incubation for 48 hours,ELISA was used to detect the levels of interleukin-8（ IL-8） and vascular endothelial growth factor（ VEGF） in the supernatants. The proliferation of HO8910 cells were detected by CCK-8 assay and the ability of invasion was determined by TranswellTMinvasion assay. CTRP6 siRNA or anti-CTRP6 antibody was used to treat HO8910 cells,and then the ability of proliferation was also detected by CCK-8 assay and the ability of migration was evaluated by wound healing experiment. Results The level of CTRP6 decreased in the sera of the patients with ovarian cancer and the supernatants of epithelial ovarian cancer cells. The levels of IL-8 and VEGF were reduced by the recombinant CTRP6 protein treatment,and the cel proliferation and invasion were also inhibited. CTRP6 siRNA or anti-CTRP6 antibody treatment promoted cel proliferation and migration. Conclusion The level of CTRP6 dropped in the sera of the patients with ovarian cancer as well as in the supernatants of epithelial ovarian cancer cells. CTRP6 could inhibit the proliferation and migration of ovarian cancer cells via blocking IL-8 / VEGF pathway.